KRYS — Krystal Biotech, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711279 ·
Last close
$309.75
Market Cap
$9.13B
52W High
$319.48
52W Low
$242.00
ADV30
285,816
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 116,357,000 | 110,034,000 | 53,689,000 | 55,932,000 | 1,396,967,000 | 501,313,000 | 120,238,000 |
| Dec 2025 | 107,105,000 | 100,513,000 | 44,270,000 | 51,400,000 | 1,333,794,000 | 496,304,000 | 114,234,000 |
| Sep 2025 | 97,800,000 | 93,537,000 | 41,374,000 | 79,365,000 | 1,240,094,000 | 392,604,000 | 102,218,000 |
| Jun 2025 | 96,042,000 | 88,877,000 | 39,307,000 | 38,333,000 | 1,138,394,000 | 353,829,000 | 97,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$250,278,000
Investing CF
$-67,231,000
Financing CF
$10,712,000
CapEx
$-12,895,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.48
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$80,095,000
Inventory
$42,646,000
Receivables
$127,022,000
ST Investments
$322,092,000
EBIT TTM
$178,640,000
Pretax Income TTM
$207,315,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$417,304,000
EBITDA
$180,468,000
Free Cash Flow
$137,491,504
Enterprise Value
$8,081,518,080
Total Cash
$823,404,992
Total Debt
$9,112,000
Shares Out
29,479,756
Trailing EPS
$7.48
Book Value
$43.37
ROE
19.9%
ROA
9.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 389,130,000 | 161,295,000 | 204,831,000 | 1,333,794,000 | 114,234,000 | — | 200,865,000 |
| Dec 2024 | 290,515,000 | 103,248,000 | 89,159,000 | 1,055,838,000 | 109,458,000 | — | 123,420,000 |
| Dec 2023 | 50,699,000 | -97,117,000 | 10,932,000 | 818,355,000 | 39,714,000 | — | -88,804,000 |
| Dec 2022 | 0 | -120,196,000 | -139,975,000 | 558,450,000 | 36,219,000 | — | -100,569,000 |
TTM Snapshot
Revenues TTM
$92,397,000
NetIncome TTM
$62,488,000
OpCashFlow TTM
$0
Assets (Latest)
$1,055,838,000
Forward EPS
$10.08
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $260.00 · spot: $309.75 · call volume: 84 · put volume: 124Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | $8.52B | $54.41 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $8.48B | $71.48 | — |
| QGEN | QIAGEN N.V. | $7.79B | $37.75 | — |
| IBRX | ImmunityBio, Inc. | $7.59B | $7.25 | — |
| RGEN | REPLIGEN CORP | $7.34B | $130.13 | — |
News headlines (Yahoo Finance, 1h cache)
Exploring 3 High Growth Tech Stocks in the US Market
2026-06-09 11:38 · Yahoo
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?
2026-06-07 17:18 · Yahoo
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
2026-06-05 15:57 · Yahoo
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
US High Growth Tech Stocks with Promising Potential
2026-06-05 11:38 · Yahoo
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
2026-06-04 14:29 · Yahoo
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
2026-06-03 15:30 · Yahoo
High Growth Tech Stocks To Watch In US June 2026
2026-06-03 11:38 · Yahoo
3 High Growth Tech Stocks To Watch In The US Market
2026-06-02 11:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.